CStone Pharmaceuticals
Qinzhou Qi has a diverse work experience in the medical and clinical research field. Qinzhou started their career as a Research Intern at Beijing Anzhen Hospital in 2007. From 2010 to 2015, they worked as a Graduate Teaching Assistant at Northern Illinois University. In 2016, they joined BeiGene as a Clinical Research Scientist (Manager II). In 2018, they transitioned to a new role as the Director of Clinical Development at BeiGene. Currently, they are the Head of Medical Writing at the Stone Pharmaceutical Company, starting in July 2021.
Qinzhou Qi completed a Bachelor of Engineering (B.E.) in Biopharmaceutics at Beijing University of Chinese Medicine from 2003 to 2007. Qinzhou then pursued a Master of Science (M.S.) in Biology at Illinois Institute of Technology from 2008 to 2009. Later, from 2010 to 2015, Qinzhou earned a Doctor of Philosophy (Ph.D.) in Plant Molecular Biology from Northern Illinois University.
This person is not in any teams
This person is not in any offices
CStone Pharmaceuticals
CStone is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established at the end of 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. With a strategic emphasis on immuno-oncology combination therapies, the Company has built an oncology-focused pipeline of 16 drug candidates, including 5 late-stage candidates at pivotal trials or registration stages. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone’s vision is to become a world-renowned biopharmaceutical company that is leading the way to conquering cancer.